Isatuximab Plus Lenalidomide, Bortezomib, and Dexamethasone (Isa-RVd) as Induction Therapy in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma: Primary Analysis of Parallel Phase 2 Studies by the Dana-Farber Cancer Institute (DFCI) and Cancer Trials Ireland (CTI)

The RRO highlights that isatuximab combined with RVd as induction therapy produced deep and rapid responses in transplant-eligible patients with newly diagnosed multiple myeloma. The regimen was generally well tolerated with a favorable safety profile, and early molecular responses were observed in a meaningful proportion of patients.